SynthesisPsychological medicine2026
Shared genetic architecture of gray matter deficits in schizophrenia and bipolar disorder: evidence from structural neuroimaging-genetic analyses.
Synthesis in Psychological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSchizophrenia (SCZ) and bipolar disorder (BD) share substantial clinical and neuroanatomical features, yet the neurogenetic basis underlying their shared gray matter volume (GMV) deficits remains poorly understood.
methodsWe conducted meta-analyses to identify convergent GMV alterations across the two disorders. Genome-wide association studies (GWAS) were performed to uncover genetic variants associated with the shared GMV deficits region in UK Biobank participants. Polygenic risk score (PRS)-GMV associations were analyzed to examine the cumulative influence of genetic risk on GMV in regions with shared deficits. Furthermore, pleiotropic SNPs jointly associated with SCZ, BD, and shared GMV deficits were identified. Spatiotemporal gene expression profiling was utilized to characterize the developmental trajectories, and molecular docking was performed to explore potential drugs.
resultsMeta-analysis revealed consistent overlapping GMV reductions in frontal, temporal, and insular regions across SCZ and BD, based on 6,620 patients and 7,762 controls. GWAS identified 14 SNPs associated with the shared GMV deficits. PRS analyses showed that modestly higher SCZ polygenic risk correlated with decreased GMV of shared regions. Two pleiotropic SNPs - rs11191368 and rs79668541 - were linked to both disorders and the shared GMV deficits. Spatiotemporal expression analyses demonstrated distinct developmental trajectories, and molecular docking highlighted 168 drugs with binding interactions for shared genes.
conclusionsThis study delineates shared neurogenetic mechanisms linking GMV abnormalities to genetic risk across SCZ and BD. Given the cross-sectional design, future longitudinal studies in independent cohorts are warranted to validate these findings and clarify the temporal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.